Selank and Semax are usually named in one breath, and they come from different parent molecules entirely. Semax is built from a fragment of adrenocorticotropic hormone; Selank is built from a fragment of tuftsin, an immune-active tetrapeptide. Both were developed in the same Russian research tradition, both solve the same engineering problem in the same way, and that shared solution — not a shared origin — is what makes them a natural pair.
Two parents, one design pattern
| Semax | Selank | |
|---|---|---|
| Parent molecule | ACTH, residues 4–10 | Tuftsin, a 4-residue immune peptide |
| Active fragment | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg |
| Added stabiliser | Pro-Gly-Pro at the C-terminus | Pro-Gly-Pro at the C-terminus |
| Retained from parent | No corticotropic activity | Immune-modulatory context |
The Pro-Gly-Pro tripeptide appears on both, and it is the whole engineering story. Short peptides are cleared rapidly by exopeptidases chewing inward from the ends; a proline-rich tail resists that attack, because proline's ring constrains the backbone in a way most peptidases cannot accommodate. Bolting Pro-Gly-Pro onto a short active fragment is a general-purpose way of buying it time, and it is the reason two unrelated fragments ended up looking like siblings.
Why does Semax not behave like ACTH?
Because the part of ACTH that drives steroid release is not in it. ACTH is 39 residues, and its melanocortin receptor activity depends on a region outside the 4–10 fragment. Taking residues 4–10 keeps a stretch associated with central nervous system effects in the older literature and discards the endocrine activity — which is the point of the fragment rather than an accident of it. This is a recurring pattern in peptide design: a protein hormone has separable regions, and a fragment can be chosen to keep one and drop another. It also means findings about ACTH transfer to Semax only where the relevant region is the one doing the work, which is rarely the case.
What does the Pro-Gly-Pro tail actually do?
It protects the molecule from being degraded from its ends, and it is not inert. Pro-Gly-Pro is itself a known biologically active fragment in other contexts, so describing it as a neutral stabiliser is a simplification. What can be said confidently is that its presence substantially extends how long the parent fragment survives against peptidases, and that both compounds were designed around it. Whether it contributes activity of its own in these two molecules is a genuinely open question rather than a settled one.
What the literature actually establishes
This is where reading these two requires more care than most compounds, and the reason is structural rather than scientific. Both have been studied for decades, with a substantial published record concentrated in Russian-language journals from a small number of institutions. The same conditions apply as to the peptide bioregulator group: a large literature is not automatically a broad one.
Three specific reading problems recur:
- Translation and indexing. Much of the primary work is not indexed in the databases most searches reach, so an English-language search returns reviews citing reviews rather than the underlying studies.
- Proposed mechanisms that are downstream observations. Both compounds are frequently described as modulating BDNF expression or monoamine systems. Those are measurements of what changed, not identifications of what was bound.
- No established receptor. Neither has a named receptor with a measured affinity. As with many short regulatory peptides, the mechanistic account is pathway-level.
Is there a receptor for either compound?
Not an established one. This does not mean they are inactive — a molecule can act through transporters, through enzyme modulation, or through a receptor nobody has identified yet. It does mean that the standard pharmacological toolkit is unavailable: no binding assay, no selective antagonist to confirm that an observed effect runs through the proposed path, no EC50 to compare across compounds. Work with these two is therefore phenotype-driven by necessity, and controls carry more of the interpretive weight than they would for a compound with a known target. Dihexa, by comparison, has a named target, which changes what an experiment can establish.
Handling
Both are short, highly soluble, and unstructured, which makes them straightforward in some respects and exposed in others.
Solubility is not the problem: both dissolve readily in water and in neutral buffers, and neither needs the acid or organic co-solvent a hydrophobic sequence would. The exposure is at low concentration, where a short unstructured peptide with charged residues can lose a meaningful fraction to the surface of the tube. Selank's arginine and lysine make it strongly basic, which increases its affinity for anything carrying a negative surface charge — glass in particular.
Do they need to be aliquoted?
Yes, for the ordinary reason rather than a special one. A vial of either that is entered repeatedly accumulates freeze–thaw cycles, and each transition concentrates solutes and moves the solution through an ice front. Single-use aliquots remove the problem entirely rather than mitigating it, and for compounds where no assay exists to confirm the material is intact, removing an uncontrolled variable is worth more than usual.
Why are they sometimes supplied in one vial?
Because the two are chemically compatible — neither carries a free cysteine, so the most common co-formulation failure mode is absent — and because the pairing is a common one in the source literature. The same trade applies as to any blend: the ratio is fixed at manufacture and cannot be varied afterwards, and the certificate has to report each component independently rather than a combined figure. Those requirements are stricter than for a single compound. Separate vials of Selank and Semax keep the proportion adjustable, which matters if the ratio is a variable rather than a setting.
Which one should a comparison start with?
Neither, as a general answer — they are not two strengths of the same thing, and a study designed to rank them against each other is usually asking a question that does not have an answer. They derive from different parents, are associated with different proposed mechanisms in the literature, and share only a stabilising tail. A comparison is informative when the readout is one both are claimed to affect, and misleading when it treats them as alternatives within one category. Two other nootropic-class peptides in the catalogue, P-21 and PE-22-28, do have named targets, which makes them the cleaner starting point for mechanism work.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
